Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.

Timmerman J, Herbaux C, Ribrag V, Zelenetz AD, Houot R, Neelapu SS, Logan T, Lossos IS, Urba W, Salles G, Ramchandren R, Jacobson C, Godwin J, Carpio C, Lathers D, Liu Y, Neely J, Suryawanshi S, Koguchi Y, Levy R

Open source

DOI: 10.1002/ajh.25757
Published: 2020 May
Container: American journal of hematology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/ajh.25757,
  title = {Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.},
  author = {Timmerman J and Herbaux C and Ribrag V and Zelenetz AD and Houot R and Neelapu SS and Logan T and Lossos IS and Urba W and Salles G and Ramchandren R and Jacobson C and Godwin J and Carpio C and Lathers D and Liu Y and Neely J and Suryawanshi S and Koguchi Y and Levy R},
  year = {2020},
  journal = {American journal of hematology},
  doi = {10.1002/ajh.25757},
  url = {https://doi.org/10.1002/ajh.25757}
}

RIS

TY  - JOUR
TI  - Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.
AU  - Timmerman J
AU  - Herbaux C
AU  - Ribrag V
AU  - Zelenetz AD
AU  - Houot R
AU  - Neelapu SS
AU  - Logan T
AU  - Lossos IS
AU  - Urba W
AU  - Salles G
AU  - Ramchandren R
AU  - Jacobson C
AU  - Godwin J
AU  - Carpio C
AU  - Lathers D
AU  - Liu Y
AU  - Neely J
AU  - Suryawanshi S
AU  - Koguchi Y
AU  - Levy R
PY  - 2020
JO  - American journal of hematology
DO  - 10.1002/ajh.25757
UR  - https://doi.org/10.1002/ajh.25757
ER  -

APA

J, T., C, H., V, R., AD, Z., R, H., SS, N., T, L., IS, L., W, U., G, S., R, R., C, J., J, G., C, C., D, L., Y, L., J, N., S, S., Y, K., & R, L. (2020). Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.. American journal of hematology. https://doi.org/10.1002/ajh.25757

Source records

pubmed · retrieved 2026-09-27T10:56:31.270Z